Tumor Antigen by Immunoassay - CA 15-3/CA 27.29

CA 15-3 (and equivalently CA 27.29) is covered when used to monitor treatment response or assess residual/recurrent breast cancer, with serial testing performed alongside other clinical assessments. Testing is not covered for initial diagnostic evaluation of patients with signs or symptoms suggestive of malignancy, and for monitoring, only one of the two tests (CA 15-3 or CA 27.29) should be used consistently rather than both.

"CA 15-3 is medically necessary to aid in the management of patients with breast cancer for monitoring response to therapy and assessing residual tumor after surgical therapy."

Sign up to see full coverage criteria, indications, and limitations.